Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4.5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. (linkinghub.elsevier.com)

Authors: Dreyling M … Hoster E Journal: The Lancet Published: 2026-05-16 DOI: https://doi.org/10.1016/S0140-6736(26)00362-4